Clinical Trial Detail

NCT ID NCT03071406
Title Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

Merkel cell carcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.